Innospec (NASDAQ:IOSP) Announces Earnings Results

Innospec (NASDAQ:IOSP) released its quarterly earnings data on Tuesday. The specialty chemicals company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.03, FiscalAI reports. Innospec had a return on equity of 9.22% and a net margin of 6.60%. The firm had revenue of $473.60 million for the quarter, compared to analyst estimates of $479.17 million. During the same quarter in the prior year, the company earned $1.12 earnings per share. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year.

Innospec Stock Performance

NASDAQ:IOSP traded down $15.31 during mid-day trading on Wednesday, reaching $83.92. 86,226 shares of the company’s stock were exchanged, compared to its average volume of 207,942. Innospec has a one year low of $65.51 and a one year high of $102.00. The firm has a market capitalization of $2.07 billion, a PE ratio of 17.32, a price-to-earnings-growth ratio of 2.65 and a beta of 0.88. The business’s fifty day simple moving average is $96.24 and its two-hundred day simple moving average is $84.60.

Innospec Announces Dividend

The firm also recently declared a dividend, which will be paid on Wednesday, November 25th. Investors of record on Tuesday, November 17th will be given a dividend of $0.94 per share. This represents a yield of 189.0%. The ex-dividend date of this dividend is Tuesday, November 17th. Innospec’s dividend payout ratio (DPR) is currently 37.55%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IOSP. Seaport Research Partners reiterated a “buy” rating and set a $110.00 target price on shares of Innospec in a research note on Thursday, August 6th. Wall Street Zen downgraded shares of Innospec from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 26th. Finally, Weiss Ratings upgraded shares of Innospec from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Two equities research analysts have rated the stock with a Hold rating. Based on data from MarketBeat, Innospec has an average rating of “Hold”.

Key Stories Impacting Innospec

Here are the key news stories impacting Innospec this week:

• Positive Sentiment: Q3 adjusted EPS was $1.29, above the $1.26 consensus and up from $1.12 a year earlier. Revenue increased 7.2% year over year to $473.6 million. Article: Innospec Q3 Earnings Beat Estimates
• Positive Sentiment: Management said all businesses contributed to revenue and operating-income growth, citing continued strength in Fuel Specialties and double-digit operating-income growth in Performance Chemicals and Oilfield Services. The company generated $17.4 million in operating cash flow and reported net cash of $251.9 million. Article: Innospec Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Innospec declared a semi-annual dividend of $0.94 per share and increased its annual dividend by 9%. Payment is scheduled for November 25 to shareholders of record on November 17. Article: Innospec Reports Strong Third-Quarter Results, Raises Annual Dividend
• Negative Sentiment: Revenue of $473.6 million missed analysts’ $479.17 million estimate. That shortfall may be weighing on sentiment despite the EPS beat and year-over-year growth. Article: Innospec Q3 Adjusted Earnings, Revenue Rise

Innospec Company Profile

Innospec Inc (NASDAQ: IOSP) is a global specialty chemicals company that develops, manufactures and markets products used in the fuel, oilfield, personal care and industrial markets. The company serves customers through a portfolio of chemical additives, formulations and technical services designed to improve product performance, efficiency and reliability.

Innospec operates through businesses focused on fuel specialties, performance chemicals and oilfield services. Its fuel-related products include fuel additives for gasoline, diesel, marine and other applications, including detergents, lubricity improvers, cetane improvers and other performance-enhancing formulations.